Premium
Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia
Author(s) -
Millot Frédéric,
Cividin Marie,
Brizard Françoise,
Chomel Jean Claude,
Méchinaud Françoise,
Guilhot François
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21938
Subject(s) - dasatinib , medicine , philadelphia chromosome , hematopoietic stem cell transplantation , stem cell , transplantation , oncology , lymphoblastic leukemia , imatinib , complete remission , leukemia , cancer research , chemotherapy , myeloid leukemia , gene , chromosomal translocation , genetics , biology
We report on the use of dasatinib, a second‐generation bcr‐abl kinase inhibitor, in a child in early relapse of Philadelphia chromosome positive acute lymphoblastic leukemia after hematopoietic stem cell transplantation. This patient benefited from the use of dasatinib obtaining of a complete molecular response which allowed a second successful transplant. Moreover, dasatinib was well tolerated in this heavily pretreated patient. Pediatr Blood Cancer 2009;52:891–892. © 2009 Wiley‐Liss, Inc.